According to the agreement, Jounce will have access to OncoSec’s gene delivery technology to assess the efficacy of intratumorally-delivered therapeutic candidates. The deal includes OncoSec’s Genesis research generator, which features customizable electroporation parameters for construct-specific optimization of expression.
The company’s Genesis research generator is the only in vivo electroporation device with Trace technology that automatically adjusts pulse width and treatment duration in real time during electroporation procedures.
“We are excited to provide a preclinical delivery solution to Jounce for early-stage research purposes and expand the data set from our delivery technologies through our Technology Access Program,” OncoSec president & CEO Punit Dhillon said in prepared remarks. “Through the establishment of these programs, OncoSec benefits from extensive, multi-party characterization and validation of our proprietary, state-of-the art electroporation technologies. We are pleased to be working with Jounce to help advance their preclinical programs with these technologies.”
“OncoSec has developed a unique delivery technology that will enable us to rapidly assess potential candidates in preclinical models,” Jounce chief scientific officer Debbie Law added. “We are delighted to be working with OncoSec and leveraging their technology to help us evaluate our preclinical immunotherapy programs.”